ClinicalTrials.gg
CompletedNCT05824091Updated Jun 4, 2026Results posted

Safety, Tolerability, Pharmacokinetics (PK), and Food Effect of MK-7762 in Healthy Adults

A Phase 1 interventional study of MK-7762 (TBD09) and Placebo in Tuberculosis, sponsored by Gates Medical Research Institute. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Gates Medical Research Institute · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.

Enrollment
32nd of 94
119 · median 56
Started
2023
with 2 others
Phase 1
44 of 129
1 open now
Registered
125th of 129
by date

Among the 129 studies in Tuberculosis with a site in United States, this one is the 32nd largest by enrollment of the 94 interventional ones that give a count, is one of 3 that started in 2023, is one of 44 in phase 1, and was the 125th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Tuberculosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of single and then multiple doses of MK-7762 (TBD09) in healthy volunteers in the context of a first-in-human study. The effect of food on the rate and extent of absorption of a single oral dose of MK-7762 (TBD09) will also be evaluated.

Read the detailed description

This is a 2-part blinded, placebo-controlled, combined single ascending dose with a food effect cohort and multiple ascending dose trial to be conducted in one trial center in the United States.

Part 1 has a single ascending dose (SAD) design with up to 5 planned dose levels. Based on the interim PK results reviewed for the dose escalation decisions, a dose will be selected for administration to a sixth cohort both in fed and fasted states to evaluate the effect of food on MK-7762 (TBD09).

Safety will be assessed throughout the study; cardiac monitoring/serial ECGs and serial blood samples will be collected for the safety and PK assessment of MK7762 (TBD09). Dose escalation to the next cohort (i.e., dose level) will not take place until the Sponsor, in conjunction with the Principal Investigator, has determined that adequate safety, tolerability (and PK for the later cohorts) from the previous cohort has been demonstrated to permit proceeding to the next cohort.

Interim PK analyses will be performed for the dose escalation decisions (after cohorts 1 and 2 are completed), to select the intermediate dose for the food effect cohort, and to reconsider the sampling time points as the trial progresses. All samples will be sent for analysis and the bioanalytical lab will be unblinded and only run the analysis on active treatment participants. At the escalation meetings, PK analyses from active treatment participants and blinded (pooled) safety summaries will be reviewed.

All participants in Part 1 will remain at the trial site from Day -1 until their end of-trial visit (approximately 8 days for Cohorts 1-5 and 16 days for Cohort 6).

At the end of Part 1, pharmacokinetic and unblinded safety data along with dose rationale for Part 2 will be sent to the Food and Drug Administration (FDA) for review and approval. The trial will not proceed to Part 2 until the FDA provides approval.

Part 2 has a multiple ascending dose (MAD) design. The dose cohorts for Part 2 will be determined based on model predictions to determine the steady-state Cmax exposure, and safety from Part 1.

In this MAD part, each participant will be administered MK7762 or matching placebo for 28 days with corresponding PK measurements. Three dose cohorts are planned. After each dose cohort, the Sponsor and Investigator will review the PK and safety data before proceeding to the next dose level.

03

Conditions studied

  • Tuberculosis

Browse trials for

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be included in this trial, an individual must satisfy all the following criteria:

  1. Is ≥ 19 to ≤ 55 years of age.
  2. Is healthy as determined by the Investigator via medical history and clinical examination before enrollment in the trial.
  3. Can understand and comply with the trial and site procedures, understand the risks involved in the trial, and provide written before the first trial-specific procedure.
  4. Can complete all Screening period evaluations and stay in the clinical research facility for the duration of the inpatient periods of the trial.
  5. Has between 18 and 32 kg/m2, inclusive, and body weight not less than 50 kg at Screening.
  6. Has resting vital signs at Screening within the following ranges: Systolic blood pressure (SBP) ≥100 mmHg Diastolic blood pressure (DBP) ≥50 mmHg Heart rate ≤100 beats per minute (bpm) Note: If vital signs are out of range, the Investigator may obtain two additional readings within the Screening period.
  7. Has a 12-lead consistent with normal cardiac conduction and function at Screening, including: HR between 45 and 100 bpm (inclusive); ≤450 ms for males and ≤470 ms for females; QRS interval \<120 ms; PR interval \<220 ms; and morphology consistent with healthy cardiac conduction.
  8. Is a nonsmoker within the previous 6 months before Screening, and does not use tobacco containing, or nicotine-containing products, including, but not limited to, cigarettes, pipes, cigars, chewing tobacco, e-cigarettes, nicotine patch, or nicotine gum.
  9. Has clinical chemistry, hematology, coagulation, and complete urinalysis (fasted for at least 8 hours) results at Screening within the reference range for the testing laboratory unless the out-of-range results are deemed not by the Investigator.
  10. Has negative results for surface antigen (HbsAg) and virus antibody (HCV Ab) within 3 months prior to Day -1 or at Screening.
  11. Has negative test results for antibody within 3 months prior to Day -1 or at Screening.
  12. Has a negative urine drug screen result at Screening and on Day -1. The presence of alcohol or marijuana in the urine is not exclusionary unless the Investigator determines that the participant's marijuana use qualifies as substance abuse (see Section 5.2, Exclusion Criteria 6).
  13. If individual's assigned sex at birth is female, they must be of non- based on either of the following: a. Is defined as amenorrhea for at least 12 months in absence of any exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the laboratory-defined postmenopausal range, or, b. Reports being surgically sterilized (i.e., tubal ligation, hysterectomy, bilateral oophorectomy/salpingectomy)
  14. If individual is assigned male sex at birth, is not sterilized, and is sexually active with a female partner of childbearing potential, agrees to use condoms from Day -1 through 90 days after the last dose of study drug. They must also agree to not donate sperm during the trial and for 3 months (90 days) after receiving the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

If an individual meets any of the following criteria, they are ineligible for this trial:

  1. Has current or past history of a cardiovascular, cerebrovascular, respiratory, gastrointestinal, hematologic, renal, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic, psychiatric, or other major disease, as determined by the Investigator.
  2. Has history of or Screening findings of abnormalities of vision, including corrected visual acuity worse than 20/25 in either eye based on Screening assessment using Snellen chart and Rosenbaum pocket chart, or color vision impairment based on Screening assessment using Ishihara plates. Candidates with ametropia corrected to 20/25 or better do not have to be excluded.
  3. Has history of or Screening findings of peripheral neuropathy, such as numbness or abnormal reflexes.
  4. Has history of or current clinically relevant cardiovascular disorder, such as heart failure, coronary artery disease, uncontrolled hypertension, arrhythmia, tachyarrhythmia, prolonged syndrome, or presence of symptom(s) strongly suggestive of such a problem, such as exertional chest pressure/pain or unexplained syncope.
  5. Had an active within 5 years from Screening, except basal cell or squamous cell skin cancers. Any history of breast cancer or melanoma will be exclusionary.
  6. Has history of any drug abuse within 1 year prior to Screening or has used any hard drugs (such as cocaine, phencyclidine [PCP], natural and synthetic opiates, and amphetamine derivatives) within 1 year prior to Screening. Individuals that have taken an opioid or amphetamine medication within the previous year prior to Screening that was prescribed by a healthcare provider will not be excluded unless they are currently taking the medication at the time of Screening.
  7. Has history of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces [150 mL)] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months of Screening or alcohol abuse within 1 year prior to Screening.
  8. Had any surgical or medical condition or history that, in the opinion of the Investigator, may potentially alter the absorption, metabolism, or excretion of study treatment, such as, but not limited to, gastric bypass or banding surgery or gastric or duodenal ulcers.
  9. Is taking any of the following prohibited medications or vaccinations: a. Any prescription or over-the-counter medication, vitamin or dietary supplement, or herbal product within 14 days prior to Day -1. b. Received any vaccination within 14 days prior to Day -1, including COVID-19 vaccination.
  10. Has a to study drugs or its and/or history of a clinically significant allergic or anaphylactic reaction to a medication.
  11. Has participated in other trials involving administration of an drug or device within 30 days or 5 half-lives, whichever is longer, before Screening for the current trial and during participation in the current trial.
  12. Has a positive PCR or antigen test result for COVID-19/SARS-CoV-2 at check-in to the Clinical Trials Unit.
  13. Has a condition that the Investigator believes would interfere with the participant's ability to provide written , comply with trial instructions, or which might confound the interpretation of the trial results or put the participant at undue risk.
  14. Has donated blood within 2 months before entering the trial or planning to donate blood during the trial or within 12 weeks after the final visit.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    MK-7762 (TBD09)

    In Part 1 of the trial (SAD/FE), up to five sequential cohorts will be enrolled to evaluate up to five escalating single doses of MK-7762; 8 participants in each cohort will be randomized (3:1) to receive MK-7762 or placebo. A sixth cohort will evaluate the effect of food on PK of single doses of MK-7762 utilizing an open-label, two-period design in 8 participants.

    Drug: MK-7762 (TBD09)

  • Placebo comparator
    Placebo

    Participants will receive placebos matched to MK-7762 (TBD09).

    Other: Placebo

Interventions

  • DrugMK-7762 (TBD09)

    Cohort 1: 50 mg Cohort 2: 150 mg Cohort 3: 300 mg Cohort 4: 600 mg Cohort 5: TBD Cohort 6: TBD

  • OtherPlacebo

    A subset of participants from each of the 6 dosing cohorts will receive placebo.

06

What researchers measure

Primary outcomes

  1. Part 1: Percentage of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

    Time frame: Day 1 through Day 7

  2. Part 1: Percentage of Participants Reporting TEAEs by Severity

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

    Time frame: Day 1 through Day 7

  3. Part 1: Percentage of Participants Reporting Study Drug Related TEAEs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

    Time frame: Day 1 through Day 7

  4. Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs, SAEs, and AESIs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

    Time frame: Up to Day 7

  5. Part 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

    Time frame: Up to Day 7

  6. Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs by Severity

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

    Time frame: Up to Day 7

  7. Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs, SAEs, and AESIs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

    Time frame: Day 1 through Day 36.

  8. Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs by Severity

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

    Time frame: Day 1 through Day 36.

  9. Part 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs

    An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

    Time frame: Day 1 through Day 36

  10. Part 1: Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and white blood cells \[WBC\]); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count

    Time frame: Up to Day 7

  11. Part 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters

    Blood samples were collected for the analysis of chemistry parameters: alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and direct bilirubin, creatinine, blood urea nitrogen (BUN) or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides.

    Time frame: Up to Day 7

  12. Part 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

    Blood samples were collected for the analysis of Serum coagulation parameters: Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and international normalized ratio (INR).

    Time frame: Up to Day 7

  13. Part 1: Number of Participants With Clinically Significant Changes in Urinalysis

    Urine samples were collected for the analysis of urinalysis parameters: Dipstick for potential of hydrogen (pH), specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.

    Time frame: Up to Day 7

  14. Part 1: Number of Participants With Clinically Significant Changes in Vital Parameters

    Vital parameters including temperature, heart rate (HR), and blood pressure (BP) were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Up to Day 7

  15. Part 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

    ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QT interval corrected by Fridericia's formula (QTcF).

    Time frame: Up to Day 7

  16. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count.

    Time frame: Up to Day 8

  17. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters

    Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count

    Time frame: Up to Day 36

  18. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters

    Blood samples were collected for the analysis of chemistry parameters: ALT, AST, ALP, total and direct bilirubin, creatinine, BUN or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).

    Time frame: Up to Day 8

  19. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters

    Participants were randomized to receive MK-7762 100 mg in a fed or fasted state.

    Time frame: Up to Day 36

  20. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

    Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.

    Time frame: Up to Day 8

  21. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis

    Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.

    Time frame: Up to Day 8

  22. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

    Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.

    Time frame: Up to Day 36

  23. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis

    Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites

    Time frame: Up to Day 36

  24. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters

    Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Up to Day 8

  25. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters

    Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

    Time frame: Up to Day 36

  26. Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters

    ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.

    Time frame: Up to Day 8

  27. Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters

    ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.

    Time frame: Up to Day 36

Secondary outcomes

  1. Part 1: Maximum Plasma Drug Concentration (Cmax) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  2. Part 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  3. Part 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  4. Part 1: AUC Over First 24h (AUC0-24) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Up to 24 hrs post dose

  5. Part 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  6. Part 1: Terminal Elimination Half-life (t½) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  7. Part 1: Oral Clearance (CL/F) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  8. Part 1: Oral Volume of Distribution (Vd/F) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

    Time frame: Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1

  9. Part 2: FE Cohort 7: Cmax of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  10. Part 2: FE Cohort 7: Tmax of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  11. Part 2: FE Cohort 7: AUClast of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  12. Part 2: FE Cohort 7: AUC0-inf of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  13. Part 2: FE Cohort 7: AUC0-24 of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Up to 24 hours post dose

  14. Part 2: FE Cohort 7: t½ of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  15. Part 2: FE Cohort 7: CL/F of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  16. Part 2: FE Cohort 7: Vd/F of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose

  17. Part 2: MAD Cohorts: CL/F of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose

  18. Part 2: MAD Cohorts: Vz/F of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose

  19. Part 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. Accumulation ratio based on AUC 0-24 was calculated as AUC tau (Day 28) /AUC 0-24 (Day 1).

    Time frame: Day 1: predose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose

  20. Part 2: MAD Cohorts: Cmax of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose

  21. Part 2: MAD Cohorts: Tmax of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose

  22. Part 2: MAD Cohorts: AUC0-24 of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Up to 24 hours post dose

  23. Part 2: MAD Cohorts: AUClast of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose

  24. Part 2: MAD Cohorts: AUC0-inf of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose

  25. Part 2: MAD Cohorts: AUC0-24 of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, 12 and 24 hours postdose

  26. Part 2: MAD Cohorts: t1/2 of MK-7762

    Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

    Time frame: Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose

07

Results

Posted Jun 4, 2026

Participant flow

This was a first-in-human trial of MK-7762, administered orally to healthy adults. It was a randomized, placebo-controlled, two-part trial. Part 1 consisted of double-blind single ascending dose (SAD) Cohorts 1 to 5, and food effect (FE) Cohort 6 (open-label). Part 2 consisted of a FE cohort 7 (open-label) and three sequential double-blind multiple ascending dose (MAD) cohorts (Cohorts 8 to 10).

Part 1: SAD Cohorts (Up to Day 7)
Participant flow — Part 1: SAD Cohorts (Up to Day 7)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started6666610000000000000
Completed6666610000000000000
Not completed000000000000000000
Part1: Period 1 FE Cohort 6(Up to Day 7)
Participant flow — Part1: Period 1 FE Cohort 6(Up to Day 7)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000350000000000
Completed000000350000000000
Not completed000000000000000000
Part1: Washout Period (8 Days)
Participant flow — Part1: Washout Period (8 Days)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000350000000000
Completed000000350000000000
Not completed000000000000000000
Part1: Period 2 FE Cohort 6(Up to Day 7)
Participant flow — Part1: Period 2 FE Cohort 6(Up to Day 7)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000350000000000
Completed000000350000000000
Not completed000000000000000000
Part 2:Period 1 FE Cohort 7(Up to Day 8)
Participant flow — Part 2:Period 1 FE Cohort 7(Up to Day 8)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000004430000000
Completed000000003330000000
Not completed000000001100000000
Withdrew: Adverse event000000001100000000
Part2: Washout Period ( 8 Days)
Participant flow — Part2: Washout Period ( 8 Days)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000003330000000
Completed000000003330000000
Not completed000000000000000000
Part 2:Period 2 FE Cohort 7(Up to Day 8)
Participant flow — Part 2:Period 2 FE Cohort 7(Up to Day 8)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000003330000000
Completed000000003330000000
Not completed000000000000000000
Part2: Washout Period (8 Days)
Participant flow — Part2: Washout Period (8 Days)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000003330000000
Completed000000003330000000
Not completed000000000000000000
Part 2:Period 3 FE Cohort 7(Up to Day 8)
Participant flow — Part 2:Period 3 FE Cohort 7(Up to Day 8)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started000000003330000000
Completed000000003330000000
Not completed000000000000000000
Part 2: MAD Cohorts (Up to Day 36)
Participant flow — Part 2: MAD Cohorts (Up to Day 36)
MilestonePart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)
Started0000000000088888812
Completed0000000000078888812
Not completed000000000001000000
Withdrew: Adverse event000000000001000000

Outcome measures

PrimaryPart 1: Percentage of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

Time frame:
Day 1 through Day 7
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Reporting Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESIs)
Percentage of participantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Any TEAE0017171720013
Any SAE00000000
Any AESI00000000
PrimaryPart 1: Percentage of Participants Reporting TEAEs by Severity

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

Time frame:
Day 1 through Day 7
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Reporting TEAEs by Severity
Percentage of participantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Mild001717010013
Moderate0000171000
Severe00000000
PrimaryPart 1: Percentage of Participants Reporting Study Drug Related TEAEs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

Time frame:
Day 1 through Day 7
Reported as:
Number · Percentage of participants
Part 1: Percentage of Participants Reporting Study Drug Related TEAEs
Percentage of participantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Percentage of Participants Reporting Study Drug Related TEAEs0000170013
PrimaryPart 2: FE Cohort 7: Percentage of Participants Reporting TEAEs, SAEs, and AESIs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

Time frame:
Up to Day 7
Reported as:
Number · Percentage of participants
Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs, SAEs, and AESIs
Percentage of participantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-Fat Meal
Any TEAE504056
Any SAE000
Any AESI000
PrimaryPart 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

Time frame:
Up to Day 7
Reported as:
Number · Percentage of participants
Part 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs
Percentage of participantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Percentage of Participants Reporting Study Drug Related TEAEs102011
PrimaryPart 2: FE Cohort 7: Percentage of Participants Reporting TEAEs by Severity

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

Time frame:
Up to Day 7
Reported as:
Number · Percentage of participants
Part 2: FE Cohort 7: Percentage of Participants Reporting TEAEs by Severity
Percentage of participantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Mild404056
Moderate1000
Severe000
PrimaryPart 2: MAD Cohorts: Percentage of Participants Reporting TEAEs, SAEs, and AESIs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. A SAE is defined as any untoward medical occurrence that, at any dose: results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent disability/incapacity or is a congenital anomaly/birth defect or is a medically significant / important event or reaction. AESIs are adverse events that the Sponsor monitored carefully and were subject to expedited reporting to the Sponsor.

Time frame:
Day 1 through Day 36.
Reported as:
Number · Percentage of participants
Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs, SAEs, and AESIs
Percentage of participantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Any TEAE75638867
Any SAE0000
Any AESI0000
PrimaryPart 2: MAD Cohorts: Percentage of Participants Reporting TEAEs by Severity

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant. The intensity for each AE reported during the study were assigned to 1 of 5 categories: Grade 1 Mild symptoms, causing no or minimal interference with usual social and functional activities with intervention not indicated; Grade 2 Moderate symptoms, causing greater than minimal interference with usual social and functional activities with intervention indicated; Grade 3 Severe symptoms, causing inability to perform usual social and functional activities with intervention or hospitalization indicated; Grade 4 Potentially life-threatening symptoms, causing inability to perform basic self-care functions with intervention indicated to prevent permanent impairment, persistent disability, or death and Grade 5: Fatal.

Time frame:
Day 1 through Day 36.
Reported as:
Number · Percentage of participants
Part 2: MAD Cohorts: Percentage of Participants Reporting TEAEs by Severity
Percentage of participantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Mild50383117
Moderate25255650
Severe0000
PrimaryPart 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs

An AE is any untoward medical occurrence in a clinical study participant whether or not considered related to the study intervention. A TEAE is any AE that occurs after receipt of one or more doses of study drug through the end of study for that participant.

Time frame:
Day 1 through Day 36
Reported as:
Number · Percentage of participants
Part 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs
Percentage of participantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Proportion of Participants Reporting Study Drug Related TEAEs25131917
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and white blood cells \[WBC\]); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Hematology Parameters
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Hematology Parameters00000000
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters

Blood samples were collected for the analysis of chemistry parameters: alanine transaminase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total and direct bilirubin, creatinine, blood urea nitrogen (BUN) or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides.

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Chemistry Parameters00000000
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

Blood samples were collected for the analysis of Serum coagulation parameters: Prothrombin Time (PT), Partial Thromboplastin Time (PTT), and international normalized ratio (INR).

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters00000000
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Urinalysis

Urine samples were collected for the analysis of urinalysis parameters: Dipstick for potential of hydrogen (pH), specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Urinalysis
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Urinalysis00000000
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Vital Parameters

Vital parameters including temperature, heart rate (HR), and blood pressure (BP) were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Vital Parameters
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Vital Parameters00000000
PrimaryPart 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters

ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QT interval corrected by Fridericia's formula (QTcF).

Time frame:
Up to Day 7
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
ParticipantsPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters00000000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-Fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Hematology Parameters000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters

Blood samples were collected for the analysis of hematology parameters: complete blood count (red blood cells, hemoglobin, platelets, and WBC); red blood cell parameters (eg, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, and red cell distribution width); white blood cell differential (absolute counts), including neutrophils, lymphocytes, monocytes, eosinophils and basophils; and reticulocyte count

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Hematology Parameters0000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters

Blood samples were collected for the analysis of chemistry parameters: ALT, AST, ALP, total and direct bilirubin, creatinine, BUN or urea, creatine kinase, sodium, potassium, bicarbonate or CO2, chloride, glucose, and lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides).

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Chemistry Parameters000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters

Participants were randomized to receive MK-7762 100 mg in a fed or fasted state.

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Chemistry Parameters0000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis

Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Urinalysis000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters

Blood samples were collected for the analysis of Serum coagulation parameters: PT, PTT, and INR.

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Serum Coagulation Parameters0000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis

Urine samples were collected for the analysis of urinalysis parameters: Dipstick for pH, specific gravity, glucose, protein, blood, leukocyte esterase, nitrites, ketones, bilirubin, and urobilinogen. Microscopic examination for red blood cells, white blood cells, casts, and bacteria was performed if urine dipstick is positive for protein, blood, leukocyte esterase, or nitrites

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Urinalysis0000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters

Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in Vital Parameters000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters

Vital parameters including temperature, HR, and BP were measured in supine position. Data for number of participants with abnormal clinically significant changes for vital signs have been presented.

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in Vital Parameters0000
PrimaryPart 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters

ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.

Time frame:
Up to Day 8
Reported as:
Count of participants · Participants
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters
ParticipantsPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed-High-fat Meal
Part 2: FE Cohort 7: Number of Participants With Clinically Significant Changes in ECG Parameters000
PrimaryPart 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters

ECG parameters included HR, RR interval, PR interval, QRS duration, QT interval, and QTcF.

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters
ParticipantsPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
Part 2: MAD Cohorts: Number of Participants With Clinically Significant Changes in ECG Parameters0000
SecondaryPart 1: Maximum Plasma Drug Concentration (Cmax) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · Micromoles
Part 1: Maximum Plasma Drug Concentration (Cmax) of MK-7762
MicromolesPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Maximum Plasma Drug Concentration (Cmax) of MK-77621.440 ± 15.53.590 ± 22.17.310 ± 30.07.240 ± 27.27.770 ± 19.16.190 ± 20.09.680 ± 17.0
SecondaryPart 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Median · Hours
Part 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-7762
HoursPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Time to Maximum Plasma Drug Concentration (Tmax) of MK-77624.50 (3.00 to 8.00)10.00 (5.00 to 24.00)10.02 (6.00 to 24.00)24.00 (8.00 to 36.00)30.01 (8.01 to 72.1)18.00 (6.00 to 24.00)7.00 (5.00 to 24.00)
SecondaryPart 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · hours*micromoles
Part 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-7762
hours*micromolesPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Area Under the Concentration-time Curve (AUC) Calculated to Last Quantifiable Observed Sample (AUClast) of MK-776243.90 ± 30.8184.0 ± 21.2309.0 ± 34.0473.0 ± 30.5676.0 ± 41.0341.0 ± 33.5394.0 ± 26.8
SecondaryPart 1: AUC Over First 24h (AUC0-24) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Up to 24 hrs post dose
Reported as:
Geometric mean · hours*micromoles
Part 1: AUC Over First 24h (AUC0-24) of MK-7762
hours*micromolesPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: AUC Over First 24h (AUC0-24) of MK-776225.80 ± 19.671.40 ± 21.5136.0 ± 25.4143.0 ± 29.6128.0 ± 18.1119.0 ± 19.9164.0 ± 17.3
SecondaryPart 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · hours*micromoles
Part 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-7762
hours*micromolesPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: AUC Extrapolated to Infinity (AUC0-inf) of MK-776250.50 ± 29.8215.0 ± 11.8326.0 ± 32.3490.0 ± 30.0486.0 ± 11.3362.0 ± 30.2406.0 ± 27.0
SecondaryPart 1: Terminal Elimination Half-life (t½) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · Hours
Part 1: Terminal Elimination Half-life (t½) of MK-7762
HoursPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Terminal Elimination Half-life (t½) of MK-776220.3 ± 15.627.4 ± 9.421.2 ± 19.721.7 ± 13.922.2 ± 14.325.3 ± 20.024.8 ± 22.9
SecondaryPart 1: Oral Clearance (CL/F) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · Liters per hour
Part 1: Oral Clearance (CL/F) of MK-7762
Liters per hourPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Oral Clearance (CL/F) of MK-77622.36 ± 29.81.67 ± 11.82.19 ± 32.32.92 ± 30.05.89 ± 11.31.98 ± 30.21.76 ± 27.0
SecondaryPart 1: Oral Volume of Distribution (Vd/F) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. In FE cohort 6 for fasted and fed conditions, data has been collected for all fasted and fed participants. The data hence has been presented for all fasted and fed participants.

Time frame:
Day 1: Pre-dose and at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose and 24 and 36 hours post-dose (Day 2); Day 3: 48 hours post-dose; Day 4: 72 hours post-dose; Day 7: Within ±1-hour time window of time of study drug administration on Day 1
Reported as:
Geometric mean · Liters
Part 1: Oral Volume of Distribution (Vd/F) of MK-7762
LitersPart 1: Cohort 1: SAD MK-7762 50 mg FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg Fed
Part 1: Oral Volume of Distribution (Vd/F) of MK-776269.3 ± 15.265.9 ± 14.267.1 ± 26.891.2 ± 27.4188 ± 10.172.0 ± 15.862.9 ± 15.9
SecondaryPart 2: FE Cohort 7: Cmax of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Nanograms per milliliter
Part 2: FE Cohort 7: Cmax of MK-7762
Nanograms per milliliterPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-high-fat MealPart 2: Cohort 7: FE 600 mg Fed-standard Meal
Part 2: FE Cohort 7: Cmax of MK-77622720 ± 18.36790 ± 10.35080 ± 25.0
SecondaryPart 2: FE Cohort 7: Tmax of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Median · Hours
Part 2: FE Cohort 7: Tmax of MK-7762
HoursPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-high-fat MealPart 2: Cohort 7: FE 600 mg Fed-standard Meal
Part 2: FE Cohort 7: Tmax of MK-776224.0 (6.00 to 48.0)8.00 (6.00 to 24.02)6.08 (6.00 to 12.10)
SecondaryPart 2: FE Cohort 7: AUClast of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: FE Cohort 7: AUClast of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-high-fat MealPart 2: Cohort 7: FE 600 mg Fed-standard Meal
Part 2: FE Cohort 7: AUClast of MK-7762179000 ± 25.3341000 ± 19.9270000 ± 24.5
SecondaryPart 2: FE Cohort 7: AUC0-inf of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: FE Cohort 7: AUC0-inf of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-high-fat MealPart 2: Cohort 7: FE 600 mg Fed-standard Meal
Part 2: FE Cohort 7: AUC0-inf of MK-7762NA ± NANA ± NANA ± NA
SecondaryPart 2: FE Cohort 7: AUC0-24 of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Up to 24 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: FE Cohort 7: AUC0-24 of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-high-fat MealPart 2: Cohort 7: FE 600 mg Fed-standard Meal
Part 2: FE Cohort 7: AUC0-24 of MK-776252800 ± 20.8125000 ± 9.294900 ± 22.3
SecondaryPart 2: FE Cohort 7: t½ of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Hours
Part 2: FE Cohort 7: t½ of MK-7762
HoursPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-High-fat MealPart 2: Cohort 7: FE 600 mg Fed-Standard Meal
Part 2: FE Cohort 7: t½ of MK-7762NA ± NANA ± NANA ± NA
SecondaryPart 2: FE Cohort 7: CL/F of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Liters per hour
Part 2: FE Cohort 7: CL/F of MK-7762
Liters per hourPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-High-fat MealPart 2: Cohort 7: FE 600 mg Fed-Standard Meal
Part 2: FE Cohort 7: CL/F of MK-7762NA ± NANA ± NANA ± NA
SecondaryPart 2: FE Cohort 7: Vd/F of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose and 24- and 36-hours post-dose (Day 2); Day 3: 48 hours; Day 4: 72 hours; Day 5: 96 hours; Day 6: 120 hours; Day 7: 144 hours; Day 8: 168 hours post dose
Reported as:
Geometric mean · Liters
Part 2: FE Cohort 7: Vd/F of MK-7762
LitersPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-High-fat MealPart 2: Cohort 7: FE 600 mg Fed-Standard Meal
Part 2: FE Cohort 7: Vd/F of MK-7762NA ± NANA ± NANA ± NA
SecondaryPart 2: MAD Cohorts: CL/F of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Reported as:
Geometric mean · Liters per hour
Part 2: MAD Cohorts: CL/F of MK-7762
Liters per hourPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: CL/F of MK-77621.90 ± 20.11.70 ± 20.12.38 ± 17.71.77 ± 19.72.64 ± 16.91.79 ± 13.5
SecondaryPart 2: MAD Cohorts: Vz/F of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Reported as:
Geometric mean · Liters
Part 2: MAD Cohorts: Vz/F of MK-7762
LitersPart 2: Cohort 8: MAD MK-7762 100 mg FastedCohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: Vz/F of MK-776262.4 ± 31.164.4 ± 13.883.7 ± 12.461.4 ± 19.590.5 ± 30.862.4 ± 14.1
SecondaryPart 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods. Accumulation ratio based on AUC 0-24 was calculated as AUC tau (Day 28) /AUC 0-24 (Day 1).

Time frame:
Day 1: predose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Reported as:
Geometric mean · Ratio
Part 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-7762
RatioPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: Accumulation Ratio (RA AUC0-24) of MK-77622.63 ± 21.82.73 ± 16.33.73 ± 15.62.78 ± 25.03.19 ± 37.12.54 ± 24.6
SecondaryPart 2: MAD Cohorts: Cmax of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · Nanograms per milliliter
Part 2: MAD Cohorts: Cmax of MK-7762
Nanograms per milliliterPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: Cmax of MK-77621040 ± 22.51180 ± 14.81880 ± 21.33550 ± 25.23100 ± 31.85860 ± 32.2
SecondaryPart 2: MAD Cohorts: Tmax of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 1: pre-dose and at 1, 2, 4, 6, 8, and 12 hours post dose; Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Median · Hours
Part 2: MAD Cohorts: Tmax of MK-7762
HoursPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: Tmax of MK-77626.00 (2.00 to 23.2)6.02 (4.00 to 12.0)17.6 (8.00 to 23.3)7.00 (6.00 to 8.03)17.6 (7.98 to 23.3)8.00 (3.98 to 12.0)
SecondaryPart 2: MAD Cohorts: AUC0-24 of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Up to 24 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: MAD Cohorts: AUC0-24 of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: AUC0-24 of MK-776220400 ± 22.921000 ± 14.835000 ± 19.462000 ± 21.260200 ± 33.3107000 ± 28.4
SecondaryPart 2: MAD Cohorts: AUClast of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours postdose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: MAD Cohorts: AUClast of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: AUClast of MK-7762108000 ± 17.1124000 ± 32.3324000 ± 24.9374000 ± 32.6526000 ± 27.1653000 ± 16.3
SecondaryPart 2: MAD Cohorts: AUC0-inf of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: MAD Cohorts: AUC0-inf of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: AUC0-inf of MK-7762110000 ± 16.5127000 ± 32.1326000 ± 24.9377000 ± 32.5532000 ± 28.0657000 ± 16.4
SecondaryPart 2: MAD Cohorts: AUC0-24 of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, 12 and 24 hours postdose
Reported as:
Geometric mean · Hours*nanograms per milliliter
Part 2: MAD Cohorts: AUC0-24 of MK-7762
Hours*nanograms per milliliterPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: AUC0-24 of MK-776252600 ± 20.158900 ± 20.1126000 ± 17.7169000 ± 19.7189000 ± 16.9279000 ± 13.5
SecondaryPart 2: MAD Cohorts: t1/2 of MK-7762

Blood samples were collected at indicated time points for the analysis of pharmacokinetic parameters. Pharmacokinetics data was calculated using standard non-compartmental analysis methods.

Time frame:
Day 28: pre-dose, and at 1, 2, 4, 6, 8, and 12 hours post dose
Reported as:
Geometric mean · Hours
Part 2: MAD Cohorts: t1/2 of MK-7762
HoursPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg Fed
Part 2: MAD Cohorts: t1/2 of MK-776222.8 ± 15.426.3 ± 18.524.4 ± 11.524.0 ± 24.623.7 ± 31.724.2 ± 21.1

Adverse events

Collected over Part 1 Cohorts 1-5 and Placebo: up to 7 days, Part 1 Cohort 6: up to 22 days (up to 7 days for each Crossover Period and 8 days Washout), Part 2 Cohort 7: up to 40 days (up to 8 days for each Crossover Period and 8 days for each Washout), Part 2 Cohorts 8-10 and Placebo: up to 36 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) Fasted0/6 (0%)0/6 (0%)0/6 (0%)
Part 1: Cohort 2: SAD MK-7762 150 mg Fasted0/6 (0%)0/6 (0%)0/6 (0%)
Part 1: Cohort 3: SAD MK-7762 300 mg Fasted0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 4: SAD MK-7762 600 mg Fasted0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Cohort 5: SAD MK-7762 1200 mg Fasted0/6 (0%)0/6 (0%)1/6 (16.7%)
Part 1: Placebo (Pooled)0/10 (0%)0/10 (0%)2/10 (20%)
Part 1: Cohort 6: FE MK-7762 300 mg Fasted0/8 (0%)0/8 (0%)0/8 (0%)
Part 1: Cohort 6: FE MK-7762 300 mg Fed0/8 (0%)0/8 (0%)1/8 (12.5%)
Part 2: Cohort 7: FE 600 mg Fasted0/10 (0%)0/10 (0%)5/10 (50%)
Part 2: Cohort 7: FE 600 mg Fed-Standard Meal0/10 (0%)0/10 (0%)4/10 (40%)
Part 2: Cohort 7: FE 600 mg Fed High-fat Meal0/9 (0%)0/9 (0%)5/9 (55.6%)
Part 2: Cohort 8: MAD MK-7762 100 mg0/16 (0%)0/16 (0%)12/16 (75%)
Part 2: Cohort 9: MAD MK-7762 300 mg0/16 (0%)0/16 (0%)10/16 (62.5%)
Part 2: Cohort 10: MAD MK-7762 500 mg0/16 (0%)0/16 (0%)14/16 (87.5%)
Part 2: Placebo (Pooled)0/12 (0%)0/12 (0%)8/12 (66.7%)
Most frequent other events
Showing 10 of 59
Most frequent other events
EventPart 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg FastedPart 1: Cohort 6: FE MK-7762 300 mg FedPart 2: Cohort 7: FE 600 mg FastedPart 2: Cohort 7: FE 600 mg Fed-Standard MealPart 2: Cohort 7: FE 600 mg Fed High-fat MealPart 2: Cohort 8: MAD MK-7762 100 mgPart 2: Cohort 9: MAD MK-7762 300 mgPart 2: Cohort 10: MAD MK-7762 500 mgPart 2: Placebo (Pooled)
HeadacheNervous system disorders0/60/60/60/60/60/100/30/52/42/43/30/160/160/160/12
Weight DecreasedInvestigations0/60/60/60/60/60/100/30/50/40/40/38/164/167/162/12
FatigueGeneral disorders0/60/60/60/60/60/100/30/51/41/41/31/160/160/160/12
Medical Device Site ReactionGeneral disorders0/60/60/60/60/60/100/30/51/41/41/32/162/160/161/12
ColitisGastrointestinal disorders0/60/60/60/60/60/100/30/51/40/40/30/160/160/160/12
NauseaGastrointestinal disorders0/60/60/60/60/60/100/30/51/40/40/30/160/160/160/12
COVID-19Infections and infestations0/60/60/60/60/60/100/30/51/41/40/31/160/160/160/12
Nasal CongestionRespiratory, thoracic and mediastinal disorders0/60/60/60/60/60/100/30/50/41/40/30/160/160/160/12
Throat IrritationRespiratory, thoracic and mediastinal disorders0/60/60/60/60/60/100/30/50/41/40/30/160/160/160/12
Abdominal DiscomfortGastrointestinal disorders0/60/60/60/60/60/100/31/50/40/40/30/160/160/161/12

Baseline characteristics

Safety Population comprised of all participants who received the study intervention.

Age, Continuous
Age, Continuous(Years)Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)Total
Mean33.3 ± 6.935.0 ± 9.342.0 ± 11.841.5 ± 10.640.2 ± 6.430.9 ± 9.040.0 ± 9.234.4 ± 10.434.5 ± 6.143.3 ± 2.836.7 ± 7.532.3 ± 7.6139.9 ± 10.238.3 ± 7.1538.9 ± 7.1240.9 ± 10.141.5 ± 6.8041.0 ± 7.037.9 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)Total
Female10211000010101212215
Male56455103543378767610104
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)Total
Hispanic or Latino10211101110222112625
Not Hispanic or Latino56455934333666776694
Unknown or Not Reported0000000000000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Cohort 1: SAD MK-7762 50 Milligrams (mg) FastedPart 1: Cohort 2: SAD MK-7762 150 mg FastedPart 1: Cohort 3: SAD MK-7762 300 mg FastedPart 1: Cohort 4: SAD MK-7762 600 mg FastedPart 1: Cohort 5: SAD MK-7762 1200 mg FastedPart 1: Placebo (Pooled)Part 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fasted/FedPart 1: Cohort 6: FE MK-7762 300 mg, Sequence: Fed/FastedPart 2: Cohort 7: FE 600 mg MK-7762, Sequence: Fasted/Standard/High-FatPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: Standard/High-Fat/FastedPart 2: Cohort 7: FE 600 mg MK-7762 Sequence: High-Fat/Fasted/StandardPart 2: Cohort 8: MAD MK-7762 100 mg FastedPart 2: Cohort 9: MAD MK-7762 300 mg FastedPart 2: Cohort 10: MAD MK-7762 500 mg FastedPart 2: Cohort 8: MAD MK-7762 100 mg FedPart 2: Cohort 9: MAD MK-7762 300 mg FedPart 2: Cohort 10: MAD MK-7762 500 mg FedPart 2: Placebo (Pooled)Total
American Indian or Alaska Native0000000000000000000
Asian0000000000001100013
Native Hawaiian or Other Pacific Islander1000000000000000001
Black or African American32124501211332422341
White24542533132445465870
More than one race0000000110010000104
Unknown or Not Reported0000000000000000000
08

Study locations

1 site
  • Investigational Site
    Lincoln, Nebraska 68502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Mar 2024, 13 months.

Results were first posted in Jun 2026, 2 years 2 months after primary completion.

Of 40 non-industry phase 1 interventional studies under Tuberculosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 30. This study's 13 months is close to that.

Counting every sponsor, half of 60 studies reached it within 10 months; a quarter within 3 and three quarters within 25.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2023
First posted
Apr 21, 2023
StartActual
Feb 23, 2023
Primary completionActual
Mar 26, 2024
CompletionActual
Mar 26, 2024
Results first posted
Jun 4, 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05824091
Lead sponsor
Gates Medical Research Institute
Responsible party
Sponsor
First posted
Apr 21, 2023
Start date
Feb 23, 2023
Primary completion
Mar 26, 2024
Completion
Mar 26, 2024
Results posted
Jun 4, 2026
Last update
Jun 4, 2026

Study contacts

Gates MRI
study director · Gates MRI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion